The percentage of effector CD4+ T cells (Foxp3−CD4+) in tumour infiltrating CD45+ cells was significantly smaller in the dual treatment group on day 2, but higher than other groups by day 5 (Supplementary Fig. 6d,e; P=0.05). Here, PTPRC is linked to neoplasm.